Insights

  • Home
  • Insights
  • The Approval and Substitutability of Biosimilars: Potential Impact on Use and Competition, Food and Drug Law Institute, Update: Enforcement Issue

Share

The Approval and Substitutability of Biosimilars: Potential Impact on Use and Competition, Food and Drug Law Institute, Update: Enforcement Issue

November 2016 External Publications
You May Also Be Interested In

April 2024 Commentary

Australia Proposes Major Reforms to Merger Review Regime

February 2024 Newsletters

EU Emergency Response Update – Key Policy & Regulatory Developments No. 112

March 2024 Alert

Federal Agencies Launch Joint Inquiry Into Private Investment in Health Care

March 2024 Alert

UK Housebuilders Avoid Immediate Regulatory Intervention, but Sector Now Faces Fresh Scrutiny on Information Exchanges

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.